Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1

MADRIGAL PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$10.32 revenue$637,320,000

Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.
Operating expenses $401.2M (R&D $174M incl upfront for CSPC, SG&A $209.1M).
Cash $1.1B; licensed global rights to oral GLP-1 (MGL-2086) from CSPC; clinic entry H1 2026.
New Orange Book patent for Rezdiffra covering weight-threshold dosing into 2045.
Launched Rezdiffra in Germany after EC conditional approval in August 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.